Contributions of ExenatideEzra

Contributions by ExenatideEzra, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 2,088 edits includes activity predating the current log.

1. 23:07, 21 Jul 2026 (diff | hist) Temperature excursion 24,964 ±0 ce per PP:MOS
2. 18:32, 17 Jul 2026 (diff | hist) Triple agonist 4,269 ±0 m de-duplicate a repeated sentence
3. 16:22, 6 May 2026 (diff | hist) Injection site rotation 4,872 ±0 unpipe a link that did not need piping
4. 13:25, 9 Apr 2026 (diff | hist) Talk:Lixisenatide 611 +128 /* Counter-example framing */ reply
5. 08:20, 19 Mar 2026 (diff | hist) Talk:Exenatide 822 +98 /* Class-effect caution */ reply
6. 09:35, 18 Mar 2026 (diff | hist) Talk:Exenatide 400 +168 /* Class-effect caution */ new section
7. 14:57, 19 Dec 2025 (diff | hist) Timeline of incretin therapeutics 4,460 ±0 m split §Pharmacology into receptor binding and downstream signalling
8. 23:59, 11 Nov 2025 (diff | hist) Dulaglutide 5,490 ±0 add the molecular formula to the infobox
9. 12:26, 1 Oct 2025 (diff | hist) Research use only 7,990 +266 clarify the difference between a marketing authorisation and a registration
10. 04:09, 23 Sep 2025 (diff | hist) Survodutide 5,445 +143 attribute the potency comparison to the head-to-head trial rather than to two separate ones
11. 11:19, 28 Jul 2025 (diff | hist) International nonproprietary name 4,000 ±0 state which salt form the mass in the infobox refers to
12. 21:08, 30 May 2025 (diff | hist) SUSTAIN trial programme 4,728 +541 rm the cross-trial comparison; the populations are not comparable
13. 13:15, 11 May 2025 (diff | hist) GLP-1 receptor 6,670 +252 convert a hard-coded date to the house format
14. 19:16, 2 Apr 2025 (diff | hist) Oral semaglutide 3,542 +23 state the substitution in one-letter code as well, per PP:MOS
15. 22:11, 22 Mar 2025 (diff | hist) Active pharmaceutical ingredient 3,435 +567 expand §The regulatory frame
16. 10:04, 3 Feb 2025 (diff | hist) Trifluoroacetate counterion 3,464 +108 m expand §Determination
17. 15:22, 26 Jan 2025 (diff | hist) Purity claim inflation 3,067 ±0 m add the second-opinion point: two services, one lot, is a stronger record
18. 23:44, 29 Dec 2024 (diff | hist) Cagrilintide 2,970 ±0 add the discontinued indication with its date
19. 14:33, 13 Dec 2024 (diff | hist) International nonproprietary name 2,241 ±0 m expand §Stems relevant here
20. 00:58, 13 Dec 2024 (diff | hist) Peptide harm reduction 2,056 ±0 correct the deductible description
21. 23:39, 8 Dec 2024 (diff | hist) CagriSema 2,861 ±0 m the half-life in the lead was the terminal figure; label it as such
22. 22:15, 4 Dec 2024 (diff | hist) GLP-1 receptor agonist 8,122 ±0 m fix indentation in the source
23. 10:10, 2 Dec 2024 (diff | hist) Amylin receptor agonist 2,905 +334 m split overlong sentence
24. 20:07, 21 Aug 2024 (diff | hist) Research use only 2,879 ±0 name the regulator rather than writing "the authorities"
25. 14:38, 21 Aug 2024 (diff | hist) Timeline of incretin therapeutics 1,845 ±0 m sentence case in headings per PP:MOS